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Background: Patients with heart failure (HF) complicated by atrial fibrillation (AF) are at significantly increased risk of all-cause mortality. While 
warfarin has been shown to improve survival in patients with AF, it is unknown whether the survival benefit observed with warfarin in randomized trials 
extends to those with HF/AF independent of other risk factors.
Methods: We conducted a retrospective cohort study using the ADHERE registry (2001 through 2006) linked to Medicare claims. Patients 
discharged home alive, naïve to anticoagulation, and without contraindications were stratified according to CHADS2 risk factors <3 and >3. We used 
propensity score methods to estimate the effect of discharge warfarin.
Results: Among 10,494 patients, those treated with warfarin had lower mortality at 1 year (27.7% vs. 39.3% in patients with CHADS2 <3 
[p<0.001], 31.6% vs. 41.8% in patients with CHADS2 >3 [p<0.001]). There was no significant difference in thromboembolic, major adverse 
cardiovascular, or bleeding events at 1 year. After multivariate adjustment, the difference in all-cause mortality between individuals exposed and 
unexposed to warfarin remained significant (Table).
Conclusions: Warfarin use in patients with HF/AF was associated with improved survival at 1 year independent of baseline risk. Further studies are 
needed to determine whether anticoagulation reduces mortality in patients with HF/AF independent of potentially unmeasured confounding in these 
observational data.
 
